TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21994429
Drug: U-100R insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-100R insulin (100 units)
Study: 10873167
Drug: Enhanced inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced inactivated poliovirus vaccine (IPV) administered intramuscularly within 24 hours of birth
Study: 9351723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CNTL) receiving intravenous crystalloid solutions
Study: 8471660
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg/day orally for at least 1 year
Study: 8471660
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (melphalan 15 mg/m2 i.v. and prednisolone 60 mg/m2 orally)
Study: 30158069
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg, enteric-coated, once daily)
Study: 7776934
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily)
Study: 24888818
Drug: Initial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial therapy (arm A)
Study: 24888818
Drug: Initial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial therapy (arm B)
Study: 24888818
Drug: Continue initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue initial therapy (arm C1)
Study: 24888818
Drug: Change to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change to alternative chemotherapy (arm C2)
Study: 22071326
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust exposure (100 μg/m(3))
Study: 15759056
Drug: Hirudin or
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin or Unfractionated heparin
Study: 12583246
Drug: Integrating Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrating Western and traditional Chinese medicine (IWTCM) including Chinese medicine and allopurinol
Study: 7756102
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg DU 29894
Study: 7756102
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg DU 29894
Study: 7756102
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flesinoxan
Study: 2110678
Drug: Tropical fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropical fish diet (500 g/day, rich in arachidonic acid and docosahexaenoic acid)
Study: 2110678
Drug: Southern fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern fish diet (500 g/day, rich in docosahexaenoic acid)
Study: 2110678
Drug: Kangaroo meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo meat diet (500 g/day, rich in linoleic and arachidonic acids)
Study: 393429
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy regimen considering circadian rhythm (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide)
Study: 393429
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy regimen without considering circadian rhythm (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide)
Study: 28356767
Drug: Guaifenesin 1200
Normalized name: guaifenesin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaifenesin 1200 mg BID
Study: 28356767
Drug: Guaifenesin 600
Normalized name: guaifenesin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guaifenesin 600 mg BID
Study: 28356767
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (for 600 mg)
Study: 25466702
Drug: Biperiden (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (2 mg)
Study: 25466702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of biperiden and citalopram
Study: 17400842
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily for 2 weeks, then 100 mg daily for 4 weeks)
Study: 17400842
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to sertraline)
Study: 15041109
Drug: Flutamide (FLU)
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide (FLU) 250 mg t.i.d. p.o.
Study: 15041109
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 100 mg t.i.d. p.o.
Study: 14728869
Drug: Bioadhesive nonoxynol-9
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive nonoxynol-9 gel
Study: 14728869
Drug: Nonoxynol-9 suppository
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 suppository
Study: 7756203
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (3 g daily)
Study: 2184795
Drug: Low-tryptophan diet
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-tryptophan diet (160 mg/d for 24 hours) followed by a 16-amino acid drink
Study: 399960
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of meglumine ioserinate (single dose)
Study: 399960
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of meglumine ioserinate (double dose)
Study: 399960
Drug: meglumine ioserinate
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meglumine ioserinate (double dose)
Study: 30449012
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 500 IU of hCG in 10 µL culture medium 4 minutes before ET
Study: 30449012
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 500 IU of hCG
Study: 28839337
Drug: AL 441
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 441 mg every 4 weeks (n = 35)
Study: 28839337
Drug: AL 882
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 882 mg every 6 weeks (n = 34)
Study: 28839337
Drug: AL 1064
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 1064 mg every 8 weeks (n = 70)
Study: 22648627
Drug: Grape extract
Normalized name: grape extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape extract supplement containing 8 mg resveratrol (Stilvid®)
Study: 19243707
Drug: Long-term statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term statin treatment for > or =6 months before PCI (statin group, 44 patients)
Study: 19243707
Drug: No long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No long-term statin treatment (nonstatin group, 56 patients)
Study: 19243707
Drug: Long-term statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term statin treatment for > or =6 months before PCI (statin group)
Study: 19243707
Drug: No long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No long-term statin treatment (nonstatin group)
Study: 17304422
Drug: Amikacin 20
Normalized name: amikacin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 20 mg/kg/d in one dose
Study: 17304422
Drug: Amikacin 10
Normalized name: amikacin 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 10 mg/kg/d every 12 hours (Control)
Study: 9880204
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + Prazosin 1 mg
Study: 9880204
Drug: Hydralazine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 30 mg + Isosorbide dinitrate 30 mg
Study: 29486502
Drug: Video Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video Capsule Endoscopy (VCE)
Study: 21622538
Drug: Oral artesunate-amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artesunate-amodiaquine
Study: 26335907
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment (RCT)
Study: 11529827
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of methylprednisolone sodium succinate on anesthetic induction (n = 6)
Study: 9382758
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa 5142/1210-Flagella Vaccine IMMUNO
Study: 8516538
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN) 40 mg/12 hours from day 6 to 20, then 40 mg/8 hours from day 21 to 100
Study: 6149939
Drug: bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 10 mg
Study: 7793217
Drug: propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 40 mg
Study: 31903689
Drug: Clinician-directed face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-directed face-to-face therapy (n = 26)
Study: 31903689
Drug: Telepractice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepractice therapy via 'SwallowIT' (n = 26)
Study: 31903689
Drug: Patient self-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-directed therapy (n = 27)
Study: 22515895
Drug: AH Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH Plus with matched‐taper single‐cone technique
Study: 22515895
Drug: MetaSEAL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MetaSEAL with matched‐taper single‐cone technique
Study: 21215227
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol (0.5 mg/kg loading dose within 1 minute followed with infusion of 0.05 mg×kg(‐1)×min(‐1))
Study: 21215227
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (loading dose: 3 mg/kg for 10 minutes, followed with intravenous infusion of 1 mg/min)
Study: 21215227
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg for 5 minutes)
Study: 12006145
Drug: Nebulized taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized taurolidine (4 mL 2% solution)
Study: 12006145
Drug: Saline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (4 mL 0.9% solution)
Study: 1827615
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of cetirizine once daily
Study: 1827615
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of terfenadine twice daily
Study: 30928825
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium (4 mg/d)
Study: 25168620
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg once daily (QD) in patients with severe renal impairment
Study: 25168620
Drug: Edoxaban with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban with co-administration of P-glycoprotein (P-gp) inhibitors
Study: 25168620
Drug: Edoxaban with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban with IV dosing and co-administration of quinidine (a P-gp inhibitor)
Study: 22374932
Drug: Group art
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group art therapy plus standard care
Study: 17476001
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (3 weeks)
Study: 15166013
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of HRT (C‐HRT) - micronized progesterone 100 mg with conjugated equine estrogen 0.625 mg daily for 2 months
Study: 15166013
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of HRT (L‐HRT) - micronized progesterone 100 mg with conjugated equine estrogen 0.3 mg daily for 2 months
Study: 15166013
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of HRT (C‐HRT)
Study: 15166013
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of HRT (L‐HRT)
Study: 7709781
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of nicardipine (2 mg injected three times each day for an average of 10 days)
Study: 3591260
Drug: 10(‐2) mol
Normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(‐2) mol l‐1 calcium ascorbate
Study: 3591260
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg kg‐1 ascorbic acid
Study: 29305946
Drug: Whole-grain diet
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain diet (50 g per 1000 kcal)
Study: 27273130
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-fluorouracil/levamisole
Study: 21311485
Drug: Akatinol memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Akatinol memantine (20 mg/day, 10 mg twice a day) for six months
Study: 17655918
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod 5%
Study: 2849682
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil supplement
Study: 10499716
Drug: Noncompliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompliance with prescription medications
Study: 10499716
Drug: Yearly medication
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yearly medication costs
Study: 7492102
Drug: Valaciclovir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1,000 mg three times daily for 7 days
Study: 7492102
Drug: Valaciclovir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1,000 mg three times daily for 14 days
Study: 8840413
Drug: Acyclovir 800
Normalized name: acyclovir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 800 mg five times daily for 7 days
Study: 27033879
Drug: Forest therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forest therapy (staying at a recreational forest site)
Study: 19443340
Drug: Pemetrexed, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed
Study: 19443340
Drug: Etoposide, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice
Study: 18097810
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (Glubosil, 30 mg)
Study: 18097810
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (Actos, 30 mg)
Study: 11581139
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in patients with ≥2 risk factors
Study: 11581139
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in patients with <2 risk factors
Study: 9699906
Drug: Gemfibrozil (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (450 mg, twice a day)
Study: 3709244
Drug: Killed influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed influenza virus vaccine
Study: 27927221
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU daily
Study: 27927221
Drug: 45000 IU
Normalized name: protease 45000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45000 IU weekly for 2 months then 400 IU daily
Study: 27927221
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU daily for 3 months then 1000 IU daily
Study: 25440793
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (5 mg twice daily)
Study: 15009069
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol 17beta 0.05 mg and norethisterone acetate 0.125 mg daily
Study: 11860772
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated hepatitis A vaccine (H2 Strain, 10^7.0 TCID(50)) after booster dose
Study: 9354540
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous furosemide (0.1 mg x kg(‐1) x h(‐1))
Study: 9354540
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous furosemide (1 mg/kg bolus every 4 hours)
Study: 3469164
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg or 300 mg b.i.d.
Study: 3469164
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d. or t.i.d.
Study: 30507559
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (1 ml lidocaine of 0.5% for each trigger point)
Study: 30507559
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection + Sham kinesiotaping
Study: 30507559
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection + kinesiotaping
Study: 30497995
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g acute dose of MSM
Study: 30497995
Drug: 1 g,
Normalized name: Sunmark Insulin Syringe 31 g, 1cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g, 3 g, or 6 g daily doses of MSM for 14 days
Study: 30497995
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g daily dose of MSM
Study: 26856517
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Swaddling and Breastfeeding
Study: 19571632
Drug: Aroma essential
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aroma essential oil inhalation
Study: 19571632
Drug: Carrier oil
Normalized name: Carrier oil-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier oil inhalation (placebo)
Study: 15230446
Drug: Owner education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Owner education (EDU) treatment group
Study: 9610790
Drug: Beta-Carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Carotene (30 mg) and Retinyl Palmitate (25,000 units) daily
Study: 7833223
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg once daily)
Study: 27050908
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine sulfate (GlcN-S) from T0 to T3, then combined treatment of mud-bath therapy and GlcN-S from T3 to T6.
Study: 27050908
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of mud-bath therapy and GlcN-S from T0 to T3, then GlcN-S alone from T3 to T6.
Study: 24351556
Drug: Rosa roxburghii
Normalized name: ROSA ROXBURGHII FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosa roxburghii tratt preparation (120 ml/d for one month)
Study: 24351556
Drug: SOD-enriched rosa
Normalized name: Rosa moschata oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOD-enriched rosa roxburghii tratt juice (120 ml/d for one month)
Study: 24351556
Drug: Rosa roxburghii
Normalized name: ROSA ROXBURGHII FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosa roxburghii tratt preparation
Study: 19166420
Drug: lafutidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LFT group)
Study: 19166420
Drug: lafutidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LFT group)
Study: 19166420
Drug: lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 7 days (7LPZ group)
Study: 19166420
Drug: lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), amoxicillin (1000 mg b.i.d.) for 14 days (14LPZ group)
Study: 31119383
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (IV-TXA)
Study: 25957542
Drug: Kaempferia parviflora
Normalized name: Kaempferia galanga root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaempferia parviflora extract (180 mg capsules once daily for 12 weeks)
Study: 17709252
Drug: Topical verapamil-nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical verapamil-nitroglycerin solution
Study: 17709252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normothermic organ bath and verapamil-nitroglycerin solution
Study: 17709252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antispasmodic treatment)
Study: 8485065
Drug: xamoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol (0.2 mg/kg)